Formula PTX Renal Stent Clinical Study

NCT ID: NCT01057316

Last Updated: 2018-06-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2018-04-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the safety and effectiveness of the PTX-coating on the Formula PTX Balloon-Expandable Stent in treatment of renal artery stenosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Artery Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Group A

Group Type EXPERIMENTAL

Formula PTX Stent - Dose 1

Intervention Type DEVICE

Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.

Study Group B

Group Type EXPERIMENTAL

Formula PTX Stent - Dose 2

Intervention Type DEVICE

Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.

Study Group C

Group Type EXPERIMENTAL

Formula PTX Stent - Dose 3

Intervention Type DEVICE

Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Formula PTX Stent - Dose 1

Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.

Intervention Type DEVICE

Formula PTX Stent - Dose 2

Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.

Intervention Type DEVICE

Formula PTX Stent - Dose 3

Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* renal artery stenosis
* appropriate size and location of the lesion

Exclusion Criteria

* pregnant or breast feeding
* failure or inability to give informed consent
* simultaneously participating in another drug or device study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cook Group Incorporated

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Ostrava

Ostrava-Poruba, , Czechia

Site Status

Institute for Clinical and Experimental Medicine

Prague, , Czechia

Site Status

Hopital Europeen Georges Pomidou

Paris, , France

Site Status

Herz-Zentrum Bad Krozingen

Bad Krozingen, , Germany

Site Status

Krankenhaus Neu-Bethlehem

Göttingen, , Germany

Site Status

Uniklinik Heidelberg

Heidelberg, , Germany

Site Status

Universitatsklinikum Leipzig AoR

Leipzig, , Germany

Site Status

St. Bonifatius Hospital

Lingen, , Germany

Site Status

Klinik Dr. Hancken im Elbe Klinikum Stade

Stade, , Germany

Site Status

Royal Sussex County Hospital

Brighton, , United Kingdom

Site Status

Kent & Canterbury Hospital

Canterbury, , United Kingdom

Site Status

St. Mary's Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Czechia France Germany United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

06-008

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Zilver® PTX® in China
NCT02171962 COMPLETED NA
BOLT Lithotripsy RESTORE ATK Trial
NCT05662787 COMPLETED NA